Home Journals Articles Updates About
CN
image
收藏切换
A case series study of the efficacy and safety of siponimod in patients with relapsing multiple sclerosis
收藏切换
PDF
Chao-yang CHEN1a, Jian-chun WANG1b, Ming-zhu XU2, Ran WEI1a, Ran LIU1b, Feng GAO1b, Yun YUAN1b, Ying ZHOU1a, 1c
Chinese Journal of Clinical Pharmacology | 2025, 41(20) : 2863 - 2868
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(20): 2863-2868
• Clinical and Basic Bridging Research •
A case series study of the efficacy and safety of siponimod in patients with relapsing multiple sclerosis
Full
Chao-yang CHEN1a, Jian-chun WANG1b, Ming-zhu XU2, Ran WEI1a, Ran LIU1b, Feng GAO1b, Yun YUAN1b, Ying ZHOU1a, 1c
Affiliations
  • 1a.Peking University First Hospital Department of Pharmacy, Beijing 100034, China
  • 1b.Peking University First Hospital Department of neurology, Beijing 100034, China
  • 1c.Peking University First Hospital Drug Clinical Trial Institution, Beijing 100034, China
  • 2.China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
Published: 2025-10-28 doi: 10.13699/j.cnki.1001-6821.2025.20.003
Outline
收藏切换
Objective

To evaluate the clinical efficacy and safety of siponimod tablets in patients with relapsing multiple sclerosis (RMS) through a case series study.

Methods

Patients meeting inclusion criteria from the department of neurology were enrolled. Demographic data, disease characteristics, medication history and laboratory/imaging results were collected. Efficacy was assessed at baseline, 3 months and 6 months after siponimod tablets medication using 3 dimensions: the expanded disability status scale (EDSS), patient-reported outcomes (PRO), and disease activity. Safety was concurrently evaluated.

Results

A total of 7 patients were included. After 6 months of siponimod tablets treatment, median EDSS score decreased from 7.00 to 6.50; EQ-5D-5L utility index median increased from -0.06 to 0.20; EQ-5D-5L VAS median score rose from 52.86 to 63.57; MSIS-29v2 physical mean score decreased from 64.52 to 54.52; MSIS-29v2 psychological mean score declined from 51.85 to 44.44; MSWS-12 mean score reduced from 80.06 to 75.00. Magnetic resonance imaging (MRI) results indicated decreased disease activity, which was also observed in patients converting from teriflunomide to siponimod treatment. Adverse drug reactions including lymphopenia (2 cases), elevated transaminases (1 case) and hypertension (1 case) were all considered treatment-related.

Conclusion

Siponimod tablets may be a therapeutic option for RMS patients, though larger studies are needed to confirm efficacy. Pre-treatment assessment of complete blood count and liver function is essential. If clinically significant adverse drug reactions occur during the treatment period, adjustments to the dosage or combined medication should be considered.

siponimod tablet  /  multiple sclerosis  /  efficacy  /  safety  /  case sery
Chao-yang CHEN, Jian-chun WANG, Ming-zhu XU, Ran WEI, Ran LIU, Feng GAO, Yun YUAN, Ying ZHOU. A case series study of the efficacy and safety of siponimod in patients with relapsing multiple sclerosis[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (20) : 2863 -2868 . DOI: 10.13699/j.cnki.1001-6821.2025.20.003
Appendix
Less
Year 2025 volume 41 Issue 20
PDF
226
121
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.20.003
  • Receive Date：2025-07-30
  • Online Date：2026-08-07
  • Published：2025-10-28
Article Data
Affiliations
History
  • Received：2025-07-30
Funding
Affiliations
    1a.Peking University First Hospital Department of Pharmacy, Beijing 100034, China
    1b.Peking University First Hospital Department of neurology, Beijing 100034, China
    1c.Peking University First Hospital Drug Clinical Trial Institution, Beijing 100034, China
    2.China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.20.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House